Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May

U.S. equities advanced on Wednesday, with the Dow, NASDAQ, and S&P 500 all posting gains, mirroring strength in European markets. This occurred as U.S. wholesale inventories in May declined 0.3% month-over-month, aligning with preliminary estimates. Sector performance saw communication services jump 1.6%, while energy dipped 0.6%, and key commodities like oil and copper traded lower. Notable individual movers included Calidi Biotherapeutics soaring over 240% on healthcare developments and RxSight plummeting 40% following a significant cut to its 2025 revenue guidance, underscoring the impact of company-specific news.

Analysis

U.S. equity markets demonstrated broad strength, with the Dow Jones, NASDAQ, and S&P 500 advancing 0.46%, 0.95%, and 0.60% respectively. This positive sentiment occurred alongside a 0.3% month-over-month decline in U.S. wholesale inventories for May, a figure that met preliminary estimates and reversed a 0.1% increase from the prior month. Sector performance was divergent, with communication services shares gaining a robust 1.6% while the energy sector fell 0.6%, a move mirrored by a 0.8% drop in oil prices to $67.82 and a sharp 3% decline in copper. The session was characterized by significant idiosyncratic stock movements driven by fundamental catalysts. RxSight, Inc. (RXST) plummeted 40% after substantially reducing its 2025 revenue guidance from a range of $160M–$175M to $120M–$130M, signaling a material deterioration in its outlook. In contrast, several small-cap firms experienced dramatic surges on company-specific news: Calidi Biotherapeutics (CLDI) soared 242% on developments in the healthcare sector, SU Group Holdings (SUGP) jumped 203% after securing an HK$88.5 million contract, and Evoke Pharma (EVOK) rose 150% upon receiving a U.S. patent notice of allowance. This market action, set against a backdrop of gains in Europe and mixed results in Asia, highlights a landscape where broad index strength coexists with high dispersion based on individual company performance and outlook.

Key Decisions for Investors

• Investors should immediately reassess positions in RxSight, Inc. (RXST), as the significant reduction in 2025 revenue guidance fundamentally alters the company's growth trajectory and valuation.
• The extreme rallies in Calidi Biotherapeutics (CLDI), SU Group (SUGP), and Evoke Pharma (EVOK) are catalyst-driven and highly volatile; consider trimming positions to realize profits or avoid chasing these parabolic moves.
• The divergence between strengthening communication services and weakening energy and industrial commodities, particularly copper, warrants monitoring as it may signal a rotation or a shift in economic growth expectations.
• Note the 0.3% decline in wholesale inventories, which, while in line with estimates, could be an early indicator of cooling economic activity that merits close observation in subsequent data releases.